Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA.
Schools of Medicine and Pharmacy, University of Missouri-Kansas City, MO, USA.
Br J Clin Pharmacol. 2022 Oct;88(10):4267-4284. doi: 10.1111/bcp.14821. Epub 2021 Apr 15.
Developmental changes that occur throughout childhood have long been known to impact drug disposition. However, pharmacokinetic studies in the paediatric population have historically been limited due to ethical concerns arising from incorporating children into clinical trials. As such, much of the early work in the field of developmental pharmacology was reliant on difficult-to-interpret in vitro and in vivo animal studies. Over the last 2 decades, our understanding of the mechanistic processes underlying age-related changes in drug disposition has advanced considerably. Progress has largely been driven by technological advances in mass spectrometry-based methods for quantifying proteins implicated in drug disposition, and in silico tools that leverage these data to predict age-related changes in pharmacokinetics. This review summarizes our current understanding of the impact of childhood development on drug disposition, particularly focusing on research of the past 20 years, but also highlighting select examples of earlier foundational research. Equally important to the studies reviewed herein are the areas that we cannot currently describe due to the lack of research evidence; these gaps provide a map of drug disposition pathways for which developmental trends still need to be characterized.
儿童期发生的发育变化长期以来一直被认为会影响药物处置。然而,由于将儿童纳入临床试验引起的伦理问题,儿科人群的药代动力学研究在历史上一直受到限制。因此,该领域的许多早期工作依赖于难以解释的体外和体内动物研究。在过去的 20 年中,我们对药物处置中与年龄相关变化相关的机制过程的理解有了很大的提高。这主要得益于基于质谱的定量方法在定量药物处置中涉及的蛋白质方面的技术进步,以及利用这些数据预测药代动力学中与年龄相关变化的计算工具。本文综述了我们目前对儿童发育对药物处置的影响的理解,特别是重点介绍了过去 20 年的研究,但也强调了早期基础研究的一些选择示例。与本文综述的研究同样重要的是,由于缺乏研究证据,我们目前无法描述的领域;这些差距为发育趋势仍需要特征化的药物处置途径提供了一张地图。